Blair William & Co. IL Sells 2,236 Shares of Insmed Incorporated (NASDAQ:INSM)

Blair William & Co. IL lowered its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 14.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 12,863 shares of the biopharmaceutical company’s stock after selling 2,236 shares during the quarter. Blair William & Co. IL’s holdings in Insmed were worth $862,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its holdings in Insmed by 8.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 135 shares during the period. CWM LLC boosted its holdings in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 155 shares during the period. First Horizon Advisors Inc. boosted its holdings in Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 287 shares during the period. Beacon Financial Advisory LLC boosted its holdings in Insmed by 4.6% during the 2nd quarter. Beacon Financial Advisory LLC now owns 13,825 shares of the biopharmaceutical company’s stock valued at $926,000 after acquiring an additional 605 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its holdings in Insmed by 1.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 38,232 shares of the biopharmaceutical company’s stock valued at $1,037,000 after acquiring an additional 610 shares during the period.

Insmed Trading Up 1.1 %

Shares of NASDAQ:INSM opened at $72.63 on Wednesday. The business’s 50-day moving average is $74.46 and its 200 day moving average is $52.84. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53. The firm has a market capitalization of $10.79 billion, a P/E ratio of -13.89 and a beta of 1.11. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to the consensus estimate of $87.95 million. During the same quarter in the prior year, the company earned ($1.78) earnings per share. Insmed’s quarterly revenue was up 17.0% compared to the same quarter last year. On average, research analysts predict that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

INSM has been the subject of a number of recent analyst reports. Guggenheim boosted their price objective on Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. The Goldman Sachs Group upped their target price on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Bank of America reiterated a “buy” rating and issued a $83.00 target price on shares of Insmed in a report on Friday, July 5th. Finally, Mizuho upped their target price on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, June 7th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $81.40.

Insider Activity at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock valued at $5,765,446 in the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.